As we have previously explained, repurposing research aim is to discover if a drug, drug combination, active ingredient, nutritional product or other therapy approved for human use in one disease or condition can be used to create a medical solution in a different disease or condition. There are many examples of this drug repurposing in the clinical practice: aspirin is approved for reduction of pain and fever, but clinical testing […]
Validating the effect of a drug or vaccine is crucial to know its real power. Anaxomics participated in the SysMalVac research project, integrating data from experimental assays and identifying biomarkers of immune protection to malaria.
Systems Biology and Mechanism of Action identification can be used in nutraceutical development and health claim support issues. This links beneficial effects with proteins involved in physiological pathways and drives future guided research.
How does chocolate make you feel better? Learn how we applied Systems Biology to answer this centuries-old question through protein network and mathematical models.
Knowing personal skin-age related genetic polymorphisms is crucial to choose the best product for each costumer. Read our next post explaining how we created a line of genetically personalized cosmetics.
Learn about the hypotheses that Systems Biology generated through Anaxomics’s TPMS molecularly strengthening the health claims of our partners for the nutraceutical improvement of type 2 diabetes.
Read this post to learn how Anaxomics technology helped to molecularly strengthen the health claims of our partners for the nutraceutical improvement of type 2 diabetes.
Systems Biology offers you the molecular understanding of biological and clinical data in context. Learn what can Anaxomics’s expertise in SysBio do for your nutraceutical or cosmetic product.
Systems Biology offers a wealth of possibilities in the nutraceuticals and cosmetics fields, specially since the European legislation requires the validation of health claims.
Clinical trials are the most expensive part of the drug development process, mostly due to the large number of subjects that are required to reach statistical significance. Discover with us how Anaxomics solves this problem through clinical trial sample size reduction.